FOG Pharmaceuticals, Inc.
FOG Pharmaceuticals, Inc. is listed today as Parabilis Medicines, Inc.: market value, financials and filings are on its company page.
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2022 | $178 M | No. 4 | $50 to $250 million | equity | SEC | |
| Dec 2020 | $23 M | No. 3 | $10 to $50 million | equity | SEC | |
| Feb 2018 | $66 M | No. 2 | $50 to $250 million | equity | SEC | |
| May 2016 | $11 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
FOG Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2022).
SEC Form D · Dec 2022
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Dec 2022
That is all the official record says: FOG Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of FOG Pharmaceuticals, Inc. are on record.
Investors#
15 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Alexis Borisy | Person | not stated | not stated | Held Series F preferred stock, director (Form 3, 2026) | SEC Form 3 |
| Deerfield Healthcare Innovations Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| Deerfield Management Company, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| Deerfield Mgmt HIF, L.P | Fund or asset manager | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| Deerfield Mgmt III, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| Deerfield Private Design Fund III, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| Edward M. Fitzgerald | Person | not stated | not stated | Held Series B, C and F preferred stock, director (Form 3, 2026) | SEC Form 3 |
| RA Capital Healthcare Fund LP | Fund or asset manager | not stated | not stated | Held Series E and F preferred stock, director (Form 3, 2026) | SEC Form 3 |
| Ra Capital Management, L.P. | Fund or asset manager | not stated | not stated | Held Series E and F preferred stock, director (Form 3, 2026) | SEC Form 3 |
| RA Capital Nexus Fund III, L.P. | Fund or asset manager | not stated | not stated | Held Series E and F preferred stock, director (Form 3, 2026) | SEC Form 3 |
| Soleus Capital Management, L.P. | Fund or asset manager | not stated | not stated | Held Series F preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| Soleus GP, LLC | Other | not stated | not stated | Held Series F preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| Soleus PE GP III, LLC | Other | not stated | not stated | Held Series F preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| Soleus Private Equity Fund III, L.P. | Private equity | not stated | not stated | Held Series F preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| Soleus Private Equity GP III, LLC | Private equity | not stated | not stated | Held Series F preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 24 investors.
Largest shareholders today
Institutions holding Parabilis Medicines, Inc. shares, as of Sep 30, 2026.
- Ra Capital Management, L.P.$942 M23.29%
- FMR LLC$351 M8.68%
- ARCH Venture Management, LLC$207 M5.12%
- venBio Partners LLC$170 M4.20%
- Alphabet Inc.$159 M3.93%
- Nextech Invest Ltd.$151 M3.72%
- Cormorant Asset Management, LP$149 M3.68%
- Regeneron Pharmaceuticals, Inc.$135 M3.33%
- Janus Henderson Group Ltd.$106 M2.62%
- Siren, L.L.C.$97 M2.39%
- BlackRock, Inc.$90 M2.23%
- Farallon Capital Management, L.L.C.$76 M1.89%
- Frazier Life Sciences Management, L.P.$75 M1.86%
- Deerfield Management Company, L.P.$61 M1.50%
- Soleus Capital Management, L.P.$54 M1.34%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Gregory L. Verdine | Executive officer | Dec 2022 |
| WeiQing M. Zhou | Executive officer | Dec 2022 |
| WeiQing A. Zhou | Executive officer | May 2018 |
| Gregory L Verdine | Executive officer | Aug 2017 |
| WeiQing A Zhou | Executive officer | Aug 2017 |
| Michael L Aceti | Executive officer | Jun 2016 |
| WeiQing L Zhou | Executive officer | Jun 2016 |
| Barbara M. Weber | Director | Dec 2022 |
| Corey S. Goodman | Director | Dec 2022 |
| Edward M. Fitzgerald | Director | Dec 2022 |
| Gregory L. Verdine | Director | Dec 2022 |
| Jeffrey A. Leerink | Director | Dec 2022 |
| Krishna M. Yeshwant | Director | Dec 2022 |
| Rick M. Klausner | Director | Dec 2022 |
| Leon M. Chen | Director | Jan 2021 |
| Edward A. Fitzgerald | Director | May 2018 |
| Leon A. Chen | Director | May 2018 |
| Edward M Fitzgerald | Director | Aug 2017 |
| Gregory L Verdine | Director | Aug 2017 |
| Jeffrey A Leerink | Director | Aug 2017 |
Went public since 2026. Its SEC number is that of a company listed on a stock exchange.